Extended Data Fig. 7: Survival outcomes with radio-immunotherapy for patients with TMB-high, PD-L1-positive (immunohistochemistry (IHC) staining >=1%), PD-L1 low (IHC staining 1-49%) and PD-L1 high (IHC staining >=50%) tumors by treatment arm and for patients with Wnt-mutant tumors in the control arm.
(a) Kaplan–Meier analyses for PFS in TMB-high tumors (n = 15 patients) in the control arm (n = 9 patients) and SBRT arm (n = 6 patients) did not reveal significant differences between patients in the SBRT versus control arms (median PFS 22.05 months vs 9.16 months, log-rank P = 0.36). (b) Kaplan–Meier analyses for PFS in PD-L1 positive tumors (n = 29 patients) in the control arm (n = 12 patients) and SBRT arm (n = 17 patients) did not demonstrate significant differences (median PFS 14.62 vs 7.79 months, log-rank P = 0.68). (c) Kaplan–Meier analyses for PFS in PD-L1 low tumors (n = 14 patients) in the control arm (n = 7 patients) and SBRT arm (n = 7 patients) did not reveal significant differences between patients in the SBRT versus control arms (median PFS SBRT arm 7.56 months, control arm 6.90 months, log-rank P = 0.81). (d) Kaplan–Meier analyses for PFS in PD-L1 high tumors (n = 15 patients) in the control arm (n = 5 patients) and SBRT arm (n = 10 patients) did not reveal significant differences between patients in the SBRT versus control arms (median PFS SBRT arm 16.8 months, control arm median not reached, log-rank P = 0.55). (e) Kaplan–Meier analyses for PFS by Wnt-mutation status in the control arm (n = 30 patients) did not reveal significant differences between patients with Wnt-mutated (n = 5 patients) versus Wnt-not mutated tumors (n = 25 patients; log-rank P = 0.17). PFS: Progression Free Survival.
